Takeda Pharmaceutical
379 hedge funds and large institutions have $1.67B invested in Takeda Pharmaceutical in 2026 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 142 increasing their positions, 101 reducing their positions, and 40 closing their positions.
587% more call options, than puts
Call options by funds: $26.9M | Put options by funds: $3.91M
65% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 40
41% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 101
5% more funds holding
Funds holding: 362 → 379 (+17)
0.19% more ownership
Funds ownership: 3.11% → 3.3% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $1.82B → $1.67B (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.1M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$36.5M |
| 3 |
Millennium Management
New York
|
+$17.4M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$10.4M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$30.3M |
| 2 |
CWP
Capital Wealth Planning
Naples,
Florida
|
-$16.4M |
| 3 |
VanEck Associates
New York
|
-$9.7M |
| 4 |
D.E. Shaw & Co
New York
|
-$9.15M |
| 5 |
Goldman Sachs
New York
|
-$8.17M |
TAK Hedge Fund Activity: Q2 2026 in Review
379 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2026, worth a combined $1.67B — down 8.1% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new TAK positions and 40 closed out — a net gain of 26 holders — while 142 added to existing stakes and 101 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $41.1M. The largest seller was UBS Group, cutting an estimated $30.3M.
- 379 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2026, up from 362 in Q1 2026.
- Funds reported $1.67B of Takeda Pharmaceutical stock for Q2 2026, down 8.1% quarter-over-quarter.
- 66 funds opened new Takeda Pharmaceutical positions in Q2 2026 and 40 closed out, a net change of +26 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2026 was Fidelity Investments, an estimated $41.1M added.
- The largest Takeda Pharmaceutical seller in Q2 2026 was UBS Group, an estimated $30.3M sold.
Based on aggregated 13F filings for Q2 2026.